A detailed history of Camber Capital Management LP transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Camber Capital Management LP holds 1,500,000 shares of DNLI stock, worth $34.8 Million. This represents 0.75% of its overall portfolio holdings.

Number of Shares
1,500,000
Holding current value
$34.8 Million
% of portfolio
0.75%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$15.83 - $23.35 $23.7 Million - $35 Million
1,500,000 New
1,500,000 $30.8 Million

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.12B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Camber Capital Management LP Portfolio

Follow Camber Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Camber Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Camber Capital Management LP with notifications on news.